The legal inquiries center on potential violations of federal securities laws and breaches of fiduciary duty. Halper Sadeh is specifically examining the acquisition of Nuvalent (NUVL) by GSK plc for $124.00 per share, the sale of Catalyst Pharmaceuticals (CPRX) to Angelini Pharma S.p.A. for $31.50 per share, and the purchase of Taylor Morrison Home Corporation (TMHC) by Berkshire Hathaway Inc. for $72.50 per share. Attorneys at the firm argue that the terms of these deals may unfairly limit the ability of shareholders to solicit or receive superior competing offers.
In section Releases
Halper Sadeh Probes Acquisitions of Nuvalent, Catalyst, and TMHC
Investor rights firm Halper Sadeh LLC has launched investigations into the proposed sales of Nuvalent, Inc., Catalyst Pharmaceuticals, Inc., and Taylor Morrison Home Corporation. The firm is scrutinizing whether these multi-billion dollar transactions prioritize the interests of corporate insiders over those of the companies' ordinary shareholders.
Representing investors globally, the firm is exploring legal avenues to secure increased compensation or enhanced financial disclosures for stakeholders. These investigations operate on a contingent fee basis, meaning shareholders face no out-of-pocket costs to participate in the review of their rights. Halper Sadeh, based at One World Trade Center in New York, has a track record of pursuing corporate reforms and recoveries in securities litigation cases.
Comments (0)
No comments yet. Be the first!